Severity of psychosis syndrome and change of metabolic abnormality in chronic schizophrenia patients: Severe negative syndrome may be related to a distinct lipid pathophysiology

European Psychiatry

Volumn 29, Issue 3, 2014, Pages 167-171

  Chen, S F ^a,b   Hu, T M ^c   Lan, T H ^b,d,e   Chiu, H J ^d,f,g   Sheen, L Y ^a   Loh, E W ^b,h  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^c YULI VETERANS HOSPITAL   (Taiwan)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

^e TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^f CHUNG HWA UNIVERSITY OF MEDICAL TECHNOLOGY   (Taiwan)

^g Jianan Mental Hospital   (Taiwan)

^h Superintendent of Kaohsiung Kai Syuan Psychiatric Hospital   (Taiwan)

Author keywords

Glucose; Lipid; Metabolism; Psychosis; Schizophrenia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CHOLESTEROL; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; METABOLIC DISORDER; MIDDLE AGED; MULTIPLE REGRESSION; NEGATIVE SYNDROME; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITIVE SYNDROME; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOPHRENIA; SEX; TREATMENT DURATION; BLOOD; CHRONIC DISEASE; METABOLISM; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX; SYNDROME; TAIWAN;

ADULT; BODY MASS INDEX; CHOLESTEROL, HDL; CHRONIC DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX; SYNDROME; TAIWAN; TRIGLYCERIDES;

EID: 84896731899     PISSN: 09249338     EISSN: 17783585     Source Type: Journal    
DOI: 10.1016/j.eurpsy.2013.04.003     Document Type: Article

References (34)

1. Andreasen N.C. Negative syndrome in schizophrenia: strategies for long-term management. Adv Biochem Psychopharmacol 1985, 40:1-7.
2. Bai Y.M., Lin C.C., Chen J.Y., Lin C.Y., Su T.P., Chou P. Association of initial antipsychotic response to clozapine and long-term weight gain. Am J Psychiatry 2006, 163:1276-1279.
3. Bellino S., Rocca P., Patria L., Marchiaro L., Rasetti R., Di Lorenzo R., et al. Relationships of age at onset with clinical features and cognitive functions in a sample of schizophrenia patients. J Clin Psychiatry 2004, 65:908-914.
4. Carpenter W.T.J.R. Clinical constructs and therapeutic discovery. Schizophr Res 2004, 72:69-73.
5. Cheng J.J., Ho H., Chang C.J., Lane H.Y., Hu H.G. Positive and negative syndrome scale (PANSS): establishment and reliability study of a mandarin Chinese language version. Chin Psychiatry 1996, 10:251-258.
6. Chien I.C., Hsu J.H., Lin C.H., Bih S.H., Chou Y.J., Chou P. Prevalence of diabetes in patients with schizophrenia in Taiwan: a population-based National Health Insurance study. Schizophr Res 2009, 111:17-22.
7. Chiu H.J., Loh E.W., Lan T.H., Sou J.H., Hsieh H.C., Hu T.M. Increase of incidence of impaired fasting glucose in young schizophrenia patients. Psychiatry Clin Neurosci 2009, 63:127-128.
8. Crow T.J. Molecular pathology of schizophrenia: more than one disease process?. Br Med J 1980, 280:66-68.
9. Crow T.J. Positive and negative schizophrenic symptoms and the role of dopamine. Br J Psychiatry 1980, 137:383-386.
10. Davidson M., Harvey P.D., Powchik P., Parrella M., White L., Knobler H.Y., et al. Severity of symptoms in chronically institutionalized geriatric schizophrenic patients. Am J Psychiatry 1995, 152:197-207.
11. Fraguas D., de Castro M.J., Medina O., Parellada M., Moreno D., Graell M., et al. Does diagnostic classification of early-onset psychosis change over follow-up?. Child Psychiatry Hum Dev 2008, 39:137-145.
12. Freeman L.R., Haley-Zitlin V., Stevens C., Granholm A.C. Diet-induced effects on neuronal and glial elements in the middle-aged rat hippocampus. Nutr Neurosci 2011, 14:32-44.
13. Hayashi H. Lipid metabolism and glial lipoproteins in the central nervous system. Biol Pharm Bull 2011, 34:453-461.
14. Horrobin D.F. The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia. Schizophr Res 1998, 30:193-208.
15. Horrobin D.F., Manku M.S., Hillman H., Iain A., Glen M. Fatty acid levels in the brains of schizophrenics and normal controls. Biol Psychiatry 1991, 30:795-805.
16. Huang M.C., Lu M.L., Tsai C.J., Chen P.Y., Chiu C.C., Jian D.L., et al. Prevalence of metabolic syndrome among patients with schizophrenia or schizoaffective disorder in Taiwan. Acta Psychiatr Scand 2009, 120:274-280.
17. Hung C.F., Wu C.K., Lin P.Y. Diabetes mellitus in patients with schizophrenia in Taiwan. Prog Neuropsychopharmacol Biol Psychiatry 2005, 29:523-527.
18. Kao Y.C., Liu Y.P. Effects of age of onset on clinical characteristics in schizophrenia spectrum disorders. BMC Psychiatry 2010, 10:63.
19. Kay S.R., Opler L.A. The positive-negative dimension in schizophrenia: its validity and significance. Psychiatr Dev 1987, 5:79-103.
20. Meltzer H.Y., Perry E., Jayathilake K. Clozapine-induced weight gain predicts improvement in psychopathology. Schizoph Res 2003, 59:19-27.
21. Meltzer H.Y., Bobo W.V., Lee M.A., Cola P., Jayathilake K. A randomized trial comparing clozapine and typical neuroleptic drugs in non-treatment-resistant schizophrenia. Psychiatry Res 2010, 177:286-293.
22. Procyshyn R.M., Wasan K.M., Thornton A.E., Barr A.M., Chen E.Y., Pomarol-Clotet E., et al. Changes in serum lipids, independent of weight, are associated with changes in symptoms during long-term clozapine treatment. J Psychiatry Neurosci 2007, 32:331-338.
23. Richardson A.J., Allen S.J., Hajnal J.V., Cox I.J., Easton T., Puri B.K. Associations between central and peripheral measures of phospholipid breakdown revealed by cerebral 31-phosphorus magnetic resonance spectroscopy and fatty acid composition of erythrocyte membranes. Prog Neuropsychopharmacol Biol Psychiatry 2001, 25:1513-1521.
24. Saari K., Jokelainen J., Veijola J., Koponen H., Jones P.B., Savolainen M., et al. Serum lipids in schizophrenia and other functional psychoses: a general population northern Finland 1966 birth cohort survey. Acta Psychiatr Scand 2004, 110:279-285.
25. Saari K., Lindeman S., Koponen H., Jokelainen J., Isohanni M. Higher serum triglyceride levels in early-onset schizophrenia. Am J Psychiatry 2004, 161:176.
26. Sethom M.M., Fares S., Bouaziz N., Melki W., Jemaa R., Feki M., et al. Polyunsaturated fatty acids deficits are associated with psychotic state and negative symptoms in patients with schizophrenia. Prostaglandins Leukot Essent Fatty Acids 2010, 83:131-136.
27. Stranahan A.M., Cutler R.G., Button C., Telljohann R., Mattson M.P. Diet-induced elevations in serum cholesterol are associated with alterations in hippocampal lipid metabolism and increased oxidative stress. J Neurochem 2011, 118:611-615.
28. Wainwright P.E. Dietary essential fatty acids and brain function: a developmental perspective on mechanisms. Proc Nutr Soc 2002, 61:61-69.
29. Williams P.T., Stefanick M.L., Vranizan K.M., Wood P.D. The effects on plasma lipoproteins of a prudent weight-reducing diet, with or without exercise, in overweight men and women. N Engl J Med 1991, 325:461-466.
30. Williams P.T., Stefanick M.L., Vranizan K.M., Wood P.D. The effects of weight loss by exercise or by dieting on plasma high-density lipoprotein (HDL) levels in men with low, intermediate, and normal-to-high HDL at baseline. Metabolism 1994, 43:917-924.
31. Wood P.D., Stefanick M.L., Dreon D.M., Frey-Hewitt B., Garay S.C., Williams P.T., et al. Changes in plasma lipids and lipoproteins in overweight men during weight loss through dieting as compared with exercise. N Engl J Med 1998, 319:1173-1179.
32. Yang Y.W., Fu C.Y. Two advanced methods for adjusting the main coefficient in logistic regression. Comput Stat 2013, 28:199-218.
33. Yao J.K., Leonard S., Reddy R.D. Membrane phospholipid abnormalities in postmortem brains from schizophrenic patients. Schizophr Res 2000, 42:7-17.
34. Yao J., Stanley J.A., Reddy R.D., Keshavan M.S., Pettegrew J.W. Correlations between peripheral polyunsaturated fatty acid content and in vivo membrane phospholipid metabolites. Biol Psychiatry 2002, 52:823-830.